Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 486-490 , September 2009

Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder

Received 24 December 2007 ,Revised 16 March 2008 ,Accepted 19 March 2008.

References 

  1. Margel D, Tal R, Baniel J. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. J Urol. 2007;178(6):2297–2300
  2. Izes JK, Dyer MW, Callum MG, et al. Ca 125 as a marker of tumor activity in advanced urothelial malignancy. J Urol. 2001;165(6 Pt 1):1908–1913
  3. Paik ML, Scolieri MJ, Brown SL, et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163(6):1693–1696
  4. Buy JN, Moss AA, Guinet C, et al. MR staging of bladder carcinoma: Correlation with pathologic findings. Radiology. 1988;69(3):695–700
  5. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51(1):137–149Discussion 149–51
  6. Cook AM, Huddart RA, Jay G, et al. The utility of tumor markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer. 2000;82(12):1952–1957
  7. Chang A, Cai J, Miranda G, et al. Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J Urol. 2004;172(6 Pt 1):2182–2186
  8. Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85(12):1501–1505
  9. Chaube A, Tewari M, Singh U, et al. CA 125: A potential tumor marker for gallbladder cancer. J Surg Oncol. 2006;93(8):665–669
  10. Ammon A, Weber MH, Wallner I, et al. Expression of the tumor-associated glycoproteins MCA, CA 125, and BW 495/36-P in epithelial tumors of the kidney and the urinary bladder. Int J Biol Markers. 1994;9(4):224–230
  11. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190–9198
  12. Dorigo O, Berek JS. CA125: Megadaltons of novel opportunities. Gynecol Oncol. 2007;104(3):505–507
  13. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem. 2001;276(29):27371–27375
  14. Packer LM, Williams SJ, Callaghan S, et al. Expression of the cell surface mucin gene family in adenocarcinomas. Int J Oncol. 2004;25(4):1119–1126
  15. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5(1):50
  16. van Ingen HE, Chan DW, Hubl W, et al. Analytical and clinical evaluation of an electro-chemiluminescence immunoassay for the determination of CA 125. Clin Chem. 1998;44(12):2530–2536
  17. Kenemans P, Verstraeten AA, van Kamp GJ, et al. The second generation CA 125 assays. Ann Med. 1995;27(1):107–113
  18. Frierson HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34(6):605–609
  19. Sevinc A, Camci C, Turk HM, et al. How to interpret serum CA 125 levels in patients with serosal involvement? (A clinical dilemma). Oncology. 2003;65(1):1–6
  20. Patankar MS, Jing Y, Morrison JC, et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol. 2005;99(3):704–713
  21. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117(3):471–477

PII: S1078-1439(08)00071-9

doi: 10.1016/j.urolonc.2008.03.019

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 5 , Pages 486-490 , September 2009

Article Tools